We are currently looking for a Lab Assistant to work for a leading San Diego biotechnology company. Bio…. $15 an hour
From BioPhase Solutions – 20 Oct 2014 23:25:43 GMT
– View all San Diego jobs
Seeking a qualified chemist to join our team and start immediately with large Biotech company in San Diego!
Duties include but are not limited to:
*Responsible for manufacturing and assembly of clinical and commercial products.
*Operates productio [...]
We are a new unique food and dietary supplement manufacturing company located in North San Diego County, California. Our focus is on delivering efficacious, great tasting, mass-marketable finished products.
We currently have an immediate opening for [...]
The TRL research facility has been operating in San Diego in the heart of the biotechnology community for the last 20 years….
From DeviceSpace.com – 20 Oct 2014 20:58:32 GMT
– View all San Diego jobs
QA Document Control Associate
JOB DESCRIPTION/ QUALIFICATIONS:
?Experience with EDMS systems ideally MasterControl or Agile but will consider any system
?STRONG experience with Microsoft Office(Excel, Microsoft Word, etc) Visio is a plus
Be part of a growing and innovative organization!
Ajinomoto Althea currently has an opening for a Temporary Warehouse Assistant.
This position is responsible for receipt of all material and inventory within warehouse. The Temporary Warehouse Assist [...]
CA-San Diego, Compliance / Quality Manager. BTS Research a well-established, diverse, stable yet growing CRO in beautiful San Diego is seeking a highly motivated, detail orientated, well organized, and highly skilledManager, Quality Assurance and Compliance who loves overcoming challenges, enjoys creating and maintaining positive team relationships and shares our passion for innovation, quality work and produci
We are looking for an experienced QA/QC Supervisor/Manager with 5+ years’ experience in the food industry, ingredients preferred. Duties include:
? Writing SOPs
? Training personnel on SOPs
? complaint handling and tracking
? Implementation of pr [...]
Excellent attention to detail. Maker, Excel experience preferred Knowledgeable of biotech industry and competitors….
From netPolarity – 20 Oct 2014 18:17:07 GMT
– View all Carlsbad jobs
SAN DIEGO, Oct. 20, 2014 /PRNewswire/ – Cypher Genomics, Inc., the genome informatics company, announced today the identification of de novo KCNB1 missense mutations as a novel genetic cause of severe epileptic encephalopathy. Cypher’s co-founder and Chief Scientific Officer Ali Torkamani, Ph.D. reviewed the data today at a platform presentation at the ASHG 2014 meeting being held October 18 to 22 in San Diego. This study highlights how Cypher’s MantisTM technology, which incorporates commercial access to the Scripps Wellderly Cohort as a genome reference population, can rapidly and accurately identify novel causes of rare diseases.
“Rare diseases disproportionately affect children, and families are left with unanswered questions and monumental medical bills in seeking a diagnosis,” said Ashley Van Zeeland, Ph.D., co-founder and Chief Executive Officer of Cypher Genomics. “Accurate genome analysis and interpretation has historically been a time consuming and manual process. We developed Mantis to address this unmet need in order to rapidly and accurately find the underlying genetic causes of disease.”
The data presented today describes an 8-year-old female patient who presented with a sporadic severe partial seizure disorder and a complex and unusual medical history of neurologic disorder, which did not fit any diagnostic category. A family-based genome sequencing study was performed including whole genome sequencing and whole exome sequencing.
Researchers utilized Mantis to identify a de novo missense mutation in KCNB1 that encodes the KV2.1 voltage-gated potassium channel as the potential cause of the patient’s disorder. This was further verified and confirmed by functional studies showing a deleterious effect of the mutation on KV2.1 function leading to a loss of ion selectivity and gain of a depolarizing inward cation conductance. Subsequently, two additional patients with epileptic encephalopathy and de novo KCNB1 missense mutations that result in a similar pattern of KV2.1 dysfunction were identified.
“While each rare disease only affects a small group of patients, millions of patients around the world are affected by a rare disease, and many never receive a definitive diagnosis,” said Dr. Van Zeeland. “Cypher’s Mantis technology was developed to help clinicians give patients and families an answer to what is causing their disease and what treatments may help.”
For researchers and clinicians, Cypher is launching a limited-time, trial access program, called Mantis 5-for-5. To learn more and sign up, visit Cypher at ASHG 2014 at booth #1525 or click here. In addition, Cypher has a second platform presentation tomorrow. Abstract 317: Frequency of “ACMG-56″ Variants in Whole Genomes of Healthy Elderly will be presented by Lauren Ariniello on Tuesday, October 21 from 10:30 am to 12:30 pm in Room 29, upper level of the San Diego Convention Center.
About Cypher Genomics
Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics’ market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Through MantisTM, the genome interpretation software as a service offering, and CoralTM, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. Cypher Genomics is located in San Diego, California.
For more information about Cypher Genomics, visit www.cyphergenomics.com and connect with us on Twitter @cyphergenomics.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cypher-genomics-identifies-and-verifies-genetic-cause-of-rare-disease-epileptic-encephalopathy-761698313.html
SOURCE Cypher Genomics, Inc.